These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 2342972)

  • 1. Doxorubicin-associated flare reactions.
    Curran CF; Luce JK; Page JA
    Oncol Nurs Forum; 1990; 17(3):387-9. PubMed ID: 2342972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusion-related phlebitis.
    Danchaivijitr S; Srihapol N; Pakaworawuth S; Vaithayapiches S; Judang T; Pumsuwan V; Kachintorn K
    J Med Assoc Thai; 1995 Jul; 78 Suppl 2():S85-90. PubMed ID: 7561602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infusion phlebitis in medical and surgical patients in Siriraj Hospital.
    Danchaivijitr S; Srihapol N; Pakaworawuth S
    J Med Assoc Thai; 1995 Jul; 78 Suppl 2():S91-4. PubMed ID: 7561603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
    Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
    Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
    Kim RJ; Peterson G; Kulp B; Zanotti KM; Markman M
    Gynecol Oncol; 2005 May; 97(2):374-8. PubMed ID: 15863132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lyme disease trends--Dutchess County, New York, 1992-2000.
    Chow CC; Evans AS; Noonan-Toly CM; White D; Johnson GS; Marks SJ; Caldwell MC; Hayes EB
    Mt Sinai J Med; 2003 May; 70(3):207-13. PubMed ID: 12764540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.
    Pisters PW; Patel SR; Prieto VG; Thall PF; Lewis VO; Feig BW; Hunt KK; Yasko AW; Lin PP; Jacobson MG; Burgess MA; Pollock RE; Zagars GK; Benjamin RS; Ballo MT
    J Clin Oncol; 2004 Aug; 22(16):3375-80. PubMed ID: 15310783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
    Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
    Kimura T; Iwase K; Aono T; Nakai S; Fujii M; Nishikawa K; Matsuda C; Shimada K; Hirota M; Nasu S; Wada D; Hasegawa J; Tanaka Y
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1889-94. PubMed ID: 19011337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
    Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extra-articular steroid injection: early patient response and the incidence of flare reaction.
    Goldfarb CA; Gelberman RH; McKeon K; Chia B; Boyer MI
    J Hand Surg Am; 2007 Dec; 32(10):1513-20. PubMed ID: 18070637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of interaction of radiation therapy with doxorubicin by continuous infusion.
    Rosenthal CJ; Rotman M
    NCI Monogr; 1988; (6):285-90. PubMed ID: 3352772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous venous infusion of doxorubicin in advanced sarcomas.
    Samuels BL; Vogelzang NJ; Ruane M; Simon MA
    Cancer Treat Rep; 1987 Oct; 71(10):971-2. PubMed ID: 3652058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of heparin to lower the incidence of phlebitis induced by anti-neoplastic agents used in ovarian cancer.
    Ikeda S; Douchi T; Nagata Y
    J Obstet Gynaecol Res; 2004 Dec; 30(6):427-9. PubMed ID: 15566456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythema nodosum: 112 cases. Epidemiology, clinical aspects and histopathology].
    Bohn S; Büchner S; Itin P
    Schweiz Med Wochenschr; 1997 Jul; 127(27-28):1168-76. PubMed ID: 9324739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between incidence of phlebitis and frequency of changing IV tubing and percutaneous site.
    Nichols EG; Barstow RE; Cooper D
    Nurs Res; 1983; 32(4):247-52. PubMed ID: 6553250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease.
    Bergeron C; Thiesse P; Rey A; Orbach D; Boutard P; Thomas C; Schmitt C; Scopinaro MJ; Bernard F; Stevens M; Oberlin O
    Eur J Cancer; 2008 Feb; 44(3):427-31. PubMed ID: 18215514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.